See safety info and boxed warning. The most common adverse reactions for austedo (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis and insomnia In a cohort of 27 participants, up to 77% reported enhancements in daily activities such as speech and eating after three months of treatment.
Toccara Jones
The fda has approved austedo xr in four new tablet strengths for adults diagnosed with tardive dyskinesia and chorea associated with huntington’s disease, according to the manufacturer
